Germany's Merck KGaA Posts Higher Earnings on Organic Growth Across Units
By Adria Calatayud
Germany's Merck KGaA reported higher earnings and sales for the third quarter, helped by organic growth across its three businesses, and narrowed its outlook for the full year.
The life-sciences and chemicals group said Thursday that it made an after-tax profit of 898 million euros ($1.04 billion) for the third quarter compared with 812 million euros for the year-earlier period.
Excluding exceptional items, the company's earnings before interest, taxes, depreciation and amortization--its preferred profit metric--were 1.67 billion euros, up 3.1% on year and up 8.8% organically.
Net sales grew 5.2% organically to 5.32 billion euros. The company said solid organic growth across all sectors contributed to its performance, particularly driven by demand for pharma-production products in its life-sciences segment, rare diseases treatments in its healthcare business and semiconductor materials in its electronics unit.
Analysts had forecast third-quarter Ebitda before exceptional items of 1.56 billion euros on net sales of 5.23 billion euros, according to consensus estimates compiled by Vara Research.
For the full year, Merck confirmed its outlook, narrowing its guidance ranges but leaving the midpoints unchanged. It now expects organic sales growth of about 3% in sales and of 5% to 7% in Ebitda before exceptional items, which compares with prior forecasts of organic sales growth of 2% to 5% and of Ebitda before exceptional items increasing by 4% to 8% organically.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
November 13, 2025 01:24 ET (06:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
